COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name MedAlliance, LLC. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 18, 2026 to Nov 6, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code OOB appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P250041, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 4 Jenner, Suite 190, Irvine, CA, 92618. Recorded on P250041/S001, decision dated Nov 6, 2026.
Device categories in this collection
Drug-Eluting Percutaneous Transluminal Coronary Angioplasty Catheter.
Changes described in PMA records
The FDA recorded an approval decision on 2026-11-06 for P250041/S001, a PMA supplement to the SELUTION SLR™ 014 PTCA Drug-Eluting Balloon (product code OOB, cardiovascular; applicant MedAlliance, LLC). The supplement is listed as a Normal 180 Day Track No User Fee submission with reason Postapproval Study Protocol. This action covers the postapproval study protocol, not a new approval of the underlying device system.
The recorded statement describes the SELUTION4ISR Continued Follow-up Study, which will evaluate long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket SELUTION4ISR study, with annual follow-up through 5 years post-procedure and efforts to minimize missing long-term data. The public documentation contains no documents, so the protocol details, endpoints and any conditions of approval cannot be verified here.
Whether the follow-up study has begun, its enrollment status and any FDA-required milestones are not stated in the available data and remain unknown.
FDA approval-order wording
SELUTION4ISR Continued Follow-up Study will evaluate the long-term safety and effectiveness of the SELUTION SLR PTCA DEB in 418 subjects from the premarket study (SELUTION4ISR). Subjects will be followed annually through 5 years post-procedure, and all efforts will be made to minimize the amount of missing long-term data.
Nov 6, 2026 · Normal 180 Day Track No User FeeFDA’s recorded scope: The SELUTION SLR 014 PTCA Drug-Eluting Balloon is intended to be used after appropriate vessel preparation in patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.25 mm to 4.50 mm in diameter and lesions <= 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).
Sep 18, 2026Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.